Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase

The outbreak of SARS, a life-threatening disease, has spread over many countries around the world. So far there is no effective drug for the treatment of SARS. Stimulated by the binding mechanism of SARS-CoV M(pro) with the octapeptide AVLQSGFR reported recently as well as the “Chou's distorted...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Yi-Ru, Huang, He, Huang, Yong-Dong, Rao, Chun-Ming, Zhao, Yang, Liu, Jin-Sheng, Wu, Lei, Wei, Dong-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2006
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115688/
https://www.ncbi.nlm.nih.gov/pubmed/16242214
http://dx.doi.org/10.1016/j.peptides.2005.09.006
Descripción
Sumario:The outbreak of SARS, a life-threatening disease, has spread over many countries around the world. So far there is no effective drug for the treatment of SARS. Stimulated by the binding mechanism of SARS-CoV M(pro) with the octapeptide AVLQSGFR reported recently as well as the “Chou's distorted key” theory, we synthesized the octapeptide AVLQSGFR for conducting various biochemical experiments to investigate the antiviral potential of the octapeptide against SARS coronavirus (BJ-01). The results demonstrate that, compared with other compounds reported so far, AVLQSGFR is the most active in inhibiting replication of the SARS coronavirus, and that no detectable toxicity is observed on Vero cells under the condition of experimental concentration.

Ejemplares similares